Share-based Payment Arrangement, Expense of Cyclerion Therapeutics, Inc. from 31 Mar 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cyclerion Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2018 to 30 Sep 2025.
  • Cyclerion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $118,000, a 14% decline year-over-year.
  • Cyclerion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $468,000, a 23% decline year-over-year.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $625,000, a 41% decline from 2023.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,067,000, a 83% decline from 2022.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,252,000, a 35% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cyclerion Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $468,000 $118,000 -$20,000 -14% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $488,000 $114,000 -$70,000 -38% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $558,000 $114,000 -$67,000 -37% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $625,000 $122,000 +$19,000 +18% 01 Oct 2024 31 Dec 2024 10-K/A 12 Nov 2025 2024 FY
Q3 2024 $606,000 $138,000 -$21,000 -13% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $627,000 $184,000 -$195,000 -51% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $822,000 $181,000 -$245,000 -58% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $1,067,000 $103,000 -$1,021,000 -91% 01 Oct 2023 31 Dec 2023 10-K/A 12 Nov 2025 2024 FY
Q3 2023 $2,088,000 $159,000 -$1,503,000 -90% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $3,591,000 $379,000 -$1,320,000 -78% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $4,911,000 $426,000 -$1,341,000 -76% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $6,252,000 $1,124,000 -$1,423,000 -56% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $7,675,000 $1,662,000 -$750,000 -31% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $8,425,000 $1,699,000 -$641,000 -27% 01 Apr 2022 30 Jun 2022 10-Q 28 Jul 2023 2023 Q2
Q1 2022 $9,066,000 $1,767,000 -$545,000 -24% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $9,611,000 $2,547,000 -$660,000 -21% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $10,271,000 $2,412,000 -$1,384,000 -36% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $11,655,000 $2,340,000 -$1,613,000 -41% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $13,268,000 $2,312,000 -$1,724,000 -43% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $14,992,000 $3,207,000 -$1,262,000 -28% 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $16,254,000 $3,796,000 -$1,152,000 -23% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $17,406,000 $3,953,000 -$2,271,000 -36% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $19,677,000 $4,036,000 +$47,000 +1.2% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 $19,630,000 $4,469,000 +$860,000 +24% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $18,770,000 $4,948,000 +$1,637,000 +49% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $17,133,000 $6,224,000 +$3,219,000 +107% 01 Apr 2019 30 Jun 2019 10-Q 03 Aug 2020 2020 Q2
Q1 2019 $13,914,000 $3,989,000 +$1,481,000 +59% 01 Jan 2019 31 Mar 2019 10-Q 04 May 2020 2020 Q1
Q4 2018 $12,433,000 $3,609,000 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $3,311,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $3,005,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $2,508,000 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1

Cyclerion Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $625,000 -$442,000 -41% 01 Jan 2024 31 Dec 2024 10-K/A 12 Nov 2025 2024 FY
2023 $1,067,000 -$5,185,000 -83% 01 Jan 2023 31 Dec 2023 10-K/A 12 Nov 2025 2024 FY
2022 $6,252,000 -$3,359,000 -35% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $9,611,000 -$5,381,000 -36% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $14,992,000 -$4,638,000 -24% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
2019 $19,630,000 +$7,197,000 +58% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $12,433,000 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.